MX2022011988A - Nuevos lipidos y composiciones de nanopartículas de estos. - Google Patents

Nuevos lipidos y composiciones de nanopartículas de estos.

Info

Publication number
MX2022011988A
MX2022011988A MX2022011988A MX2022011988A MX2022011988A MX 2022011988 A MX2022011988 A MX 2022011988A MX 2022011988 A MX2022011988 A MX 2022011988A MX 2022011988 A MX2022011988 A MX 2022011988A MX 2022011988 A MX2022011988 A MX 2022011988A
Authority
MX
Mexico
Prior art keywords
sup
nanoparticle compositions
novel lipids
capsid
lipids
Prior art date
Application number
MX2022011988A
Other languages
English (en)
Inventor
Matthew G Stanton
Birte Nolting
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of MX2022011988A publication Critical patent/MX2022011988A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se proporcionan lípidos que tienen la Fórmula (I): (VER FORMULA) y sales farmacéuticamente aceptables de estos, en donde R1 , R2 , a y b son como se definen en la presente. Se proporcionan además en la presente, composiciones de nanopartículas lipídicas (LNP) que comprenden lípidos que tienen la Fórmula (I) y un vector no viral libre de cápside (por ejemplo, ADNce). En un aspecto de cualquiera de los aspectos o modalidades de la presente, estas LNP pueden usarse para suministrar un vector de ADN no viral libre de cápside a un sitio diana de interés (por ejemplo, célula, tejido, órgano y similares).
MX2022011988A 2020-03-27 2021-03-26 Nuevos lipidos y composiciones de nanopartículas de estos. MX2022011988A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063000990P 2020-03-27 2020-03-27
PCT/US2021/024413 WO2021195529A2 (en) 2020-03-27 2021-03-26 Novel lipids and nanoparticle compositions thereof

Publications (1)

Publication Number Publication Date
MX2022011988A true MX2022011988A (es) 2023-01-04

Family

ID=77890624

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011988A MX2022011988A (es) 2020-03-27 2021-03-26 Nuevos lipidos y composiciones de nanopartículas de estos.

Country Status (11)

Country Link
US (1) US20230159459A1 (es)
EP (1) EP4125821A2 (es)
JP (1) JP2023518985A (es)
KR (1) KR20220160647A (es)
CN (1) CN115916163A (es)
AU (1) AU2021241696A1 (es)
BR (1) BR112022019369A2 (es)
CA (1) CA3173126A1 (es)
IL (1) IL296763A (es)
MX (1) MX2022011988A (es)
WO (1) WO2021195529A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3114699A1 (en) 2018-10-09 2020-04-16 The University Of British Columbia Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto
CN116437964A (zh) * 2020-07-17 2023-07-14 世代生物公司 用于将多核苷酸封装成减小尺寸的脂质纳米颗粒以及其新型调配物的方法
AU2021385572A1 (en) 2020-11-25 2023-06-22 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
WO2023121964A1 (en) * 2021-12-20 2023-06-29 Beam Therapeutics Inc. Nanomaterials comprising disulfides
WO2023190164A1 (ja) * 2022-03-28 2023-10-05 日油株式会社 アリールエステルを含むカルボン酸の製造方法及びカチオン性脂質の製造方法
CN116082184B (zh) * 2023-04-12 2023-06-30 山东大学 基于环己二胺的可电离脂质、脂质纳米颗粒及其制备方法与应用
CN117964577A (zh) * 2024-03-29 2024-05-03 天津全和诚生物技术有限公司 阳离子脂质化合物、其制备方法、包含其的组合物及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4775523B1 (ja) * 2010-10-05 2011-09-21 トヨタ自動車株式会社 推定装置および推定方法
JP7075256B2 (ja) * 2018-03-28 2022-05-25 三菱重工業株式会社 配管の余寿命評価方法

Also Published As

Publication number Publication date
KR20220160647A (ko) 2022-12-06
WO2021195529A2 (en) 2021-09-30
CN115916163A (zh) 2023-04-04
BR112022019369A2 (pt) 2022-12-13
AU2021241696A1 (en) 2022-12-01
EP4125821A2 (en) 2023-02-08
IL296763A (en) 2022-11-01
US20230159459A1 (en) 2023-05-25
JP2023518985A (ja) 2023-05-09
CA3173126A1 (en) 2021-09-30
WO2021195529A3 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
MX2022011988A (es) Nuevos lipidos y composiciones de nanopartículas de estos.
MX2022006033A (es) Lipidos ionizables y composiciones de nanoparticulas de estos.
MX2022014484A (es) Lipidos nuevos y composiciones de nanoparticulas de estos.
ES2332062T3 (es) Micelas polimericas para el suministro de farmacos.
ES2208763T3 (es) Formulaciones de emulsion para el suministro de acidos nucleicos a las celulas.
Popov et al. Cationic vesicles from novel bolaamphiphilic compounds
SG173183A1 (en) Methods of reducing the proliferation and viability of microbial agents
ES2390015T3 (es) Composición cosmética que comprende un derivado difenil-metano hidroxilado
CA3009891A1 (en) Lipids, lipid compositions, and methods of using them
ES2732216T3 (es) Polímeros catiónicos a base de glucógeno
PT770140E (pt) Composição contendo ácidos nucleicos e polímeros catiónicos, sua preparação e utilização
PE20050822A1 (es) Derivados de florfenicol con mejor solubilidad en agua
BR112021025984A2 (pt) Conjugado de anticorpo-derivado de tubulisina b (análogo), composto, composição farmacêutica, e, usos do conjugado, dos compostos e das composições farmacêuticas
SE0402925D0 (sv) Novel Compounds
WO2010137354A1 (ja) 防腐剤組成物
Zhao et al. Combination of poly (ethylenimine) and chitosan induces high gene transfection efficiency and low cytotoxicity
US6344576B1 (en) Phospholipid-analogous compounds
WO2001074807A1 (fr) Derives indolylpyrrole et inhibiteurs de mort cellulaire
EP3103486A1 (en) Preparation for adhesion prevention comprising composition of polycationic triblock copolymer and polyanionic polymer
Fletcher et al. A dialkynoyl analogue of DOPE improves gene transfer of lower-charged, cationic lipoplexes
BR112021006861A2 (pt) composições e métodos para transfecção de células
KR20200081432A (ko) 조백선 치료용 외부 제제
EP1152002A4 (en) PYRROL DERIVATIVES AND CELL DEATH INHIBITORS
WO2022226008A3 (en) Cationic lipids and compositions thereof
ES2542864T3 (es) Composición portadora de administración rápida de ácidos nucleicos